← Back to Screener
Travere Therapeutics, Inc. Common Stock (TVTX)
Price$39.54
Favorite Metrics
Price vs S&P 500 (26W)52.31%
Price vs S&P 500 (4W)46.07%
Market Capitalization$3.78B
All Metrics
P/CF (Annual)99.97x
Book Value / Share (Quarterly)$1.26
P/TBV (Annual)1995.76x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)32.28%
Cash Flow / Share (Quarterly)$-0.22
Price vs S&P 500 (YTD)4.53%
Gross Margin (TTM)97.89%
Net Profit Margin (TTM)-5.21%
EPS (TTM)$-0.33
10-Day Avg Trading Volume3.52M
EPS Excl Extra (TTM)$-0.33
Revenue Growth (5Y)19.87%
EPS (Annual)$-0.29
ROI (Annual)-5.99%
Gross Margin (Annual)97.89%
Net Profit Margin (5Y Avg)-86.07%
Cash / Share (Quarterly)$3.55
Revenue Growth QoQ (YoY)73.41%
ROA (Last FY)-4.22%
Revenue Growth TTM (YoY)110.46%
EBITD / Share (TTM)$0.09
ROE (5Y Avg)-266.16%
Operating Margin (TTM)-12.80%
Cash Flow / Share (Annual)$-0.22
P/B Ratio32.90x
P/B Ratio (Quarterly)29.77x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)8.14x
Net Interest Coverage (TTM)-54.64x
ROA (TTM)-4.55%
EV / EBITDA (TTM)501.63x
EPS Incl Extra (Annual)$-0.29
Current Ratio (Annual)2.74x
Quick Ratio (Quarterly)2.52x
3-Month Avg Trading Volume2.08M
52-Week Price Return176.13%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.02
P/S Ratio (Annual)7.70x
Asset Turnover (Annual)0.81x
52-Week High$43.31
Operating Margin (5Y Avg)-123.87%
EPS Excl Extra (Annual)$-0.29
CapEx CAGR (5Y)18.81%
Tangible BV CAGR (5Y)-58.03%
26-Week Price Return56.30%
Quick Ratio (Annual)2.52x
13-Week Price Return20.09%
Total Debt / Equity (Annual)2.71x
Current Ratio (Quarterly)2.74x
Enterprise Value$3,995.981
Revenue / Share Growth (5Y)5.67%
Asset Turnover (TTM)0.87x
Book Value / Share Growth (5Y)-20.77%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.71x
Pretax Margin (Annual)-10.04%
Cash / Share (Annual)$3.55
3-Month Return Std Dev95.74%
Gross Margin (5Y Avg)96.02%
Net Income / Employee (TTM)$-0
ROE (Last FY)-22.25%
Net Interest Coverage (Annual)-29.23x
EPS Basic Excl Extra (Annual)$-0.29
P/FCF (TTM)90.34x
Receivables Turnover (TTM)9.15x
Total Debt / Equity (Quarterly)2.71x
EPS Incl Extra (TTM)$-0.33
Receivables Turnover (Annual)9.15x
ROI (TTM)-6.24%
P/S Ratio (TTM)7.70x
Pretax Margin (5Y Avg)-123.33%
Revenue / Share (Annual)$5.50
Tangible BV / Share (Annual)$0.02
Forward P/E136.46x
Price vs S&P 500 (52W)146.30%
Year-to-Date Return7.17%
5-Day Price Return30.25%
EPS Normalized (Annual)$-0.29
ROA (5Y Avg)-27.41%
Net Profit Margin (Annual)-5.21%
Month-to-Date Return37.83%
Cash Flow / Share (TTM)$-4.45
EBITD / Share (Annual)$0.09
Operating Margin (Annual)-12.80%
LT Debt / Equity (Annual)2.71x
P/CF (TTM)99.97x
ROI (5Y Avg)-39.86%
LT Debt / Equity (Quarterly)2.71x
EPS Basic Excl Extra (TTM)$-0.33
P/TBV (Quarterly)1995.76x
P/B Ratio (Annual)29.77x
Inventory Turnover (TTM)1.71x
Pretax Margin (TTM)-10.04%
Book Value / Share (Annual)$1.26
Price vs S&P 500 (13W)19.40%
Beta1.04x
Revenue / Share (TTM)$5.43
ROE (TTM)-40.24%
52-Week Low$13.88
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.24
4.24
4.24
4.24
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TVTXTravere Therapeutics, Inc. Common Stock | 7.70x | 110.46% | 97.89% | — | $39.54 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Travere Therapeutics is a biopharmaceutical company developing therapies for rare kidney, liver, and metabolic diseases. Its lead candidate, sparsentan, is in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), both rare kidney disorders that can progress to end-stage kidney disease. The company is also advancing pegtibatinase, an investigational enzyme replacement therapy for HCU, a genetic metabolic disorder.